Aspartame-induced  ||| S:0 E:18 ||| JJ
fibromyalgia ||| S:18 E:30 ||| NN
,  ||| S:30 E:32 ||| ,
an  ||| S:32 E:35 ||| DT
unusual  ||| S:35 E:43 ||| JJ
but  ||| S:43 E:47 ||| CC
curable  ||| S:47 E:55 ||| JJ
cause  ||| S:55 E:61 ||| NN
of  ||| S:61 E:64 ||| IN
chronic  ||| S:64 E:72 ||| JJ
pain  ||| S:72 E:77 ||| NN
We  ||| S:77 E:80 ||| PRP
report  ||| S:80 E:87 ||| VBP
for  ||| S:87 E:91 ||| IN
the  ||| S:91 E:95 ||| DT
first  ||| S:95 E:101 ||| JJ
time  ||| S:101 E:106 ||| NN
an  ||| S:106 E:109 ||| DT
unusual  ||| S:109 E:117 ||| JJ
musculoskeletal  ||| S:117 E:133 ||| JJ
adverse  ||| S:133 E:141 ||| JJ
effect  ||| S:141 E:148 ||| NN
of  ||| S:148 E:151 ||| IN
aspartame  ||| S:151 E:161 ||| NN
in  ||| S:161 E:164 ||| IN
two  ||| S:164 E:168 ||| CD
patients ||| S:168 E:176 ||| NNS
.  ||| S:176 E:178 ||| .
A  ||| S:178 E:180 ||| DT
50-year-old  ||| S:180 E:192 ||| JJ
woman  ||| S:192 E:198 ||| NN
had  ||| S:198 E:202 ||| VBD
been  ||| S:202 E:207 ||| VBN
suffering  ||| S:207 E:217 ||| VBG
from  ||| S:217 E:222 ||| IN
widespread  ||| S:222 E:233 ||| JJ
pain  ||| S:233 E:238 ||| NN
and  ||| S:238 E:242 ||| CC
fatigue  ||| S:242 E:250 ||| NN
for  ||| S:250 E:254 ||| IN
more  ||| S:254 E:259 ||| JJR
than  ||| S:259 E:264 ||| IN
10  ||| S:264 E:267 ||| CD
years  ||| S:267 E:273 ||| NNS
leading  ||| S:273 E:281 ||| VBG
to  ||| S:281 E:284 ||| TO
the  ||| S:284 E:288 ||| DT
diagnosis  ||| S:288 E:298 ||| NN
of  ||| S:298 E:301 ||| IN
fibromyalgia ||| S:301 E:313 ||| NN
.  ||| S:313 E:315 ||| .
During  ||| S:315 E:322 ||| IN
a  ||| S:322 E:324 ||| DT
vacation  ||| S:324 E:333 ||| NN
in  ||| S:333 E:336 ||| IN
a  ||| S:336 E:338 ||| DT
foreign  ||| S:338 E:346 ||| JJ
country ||| S:346 E:353 ||| NN
,  ||| S:353 E:355 ||| ,
she  ||| S:355 E:359 ||| PRP
did  ||| S:359 E:363 ||| VBD
not  ||| S:363 E:367 ||| RB
suffer  ||| S:367 E:374 ||| VB
from  ||| S:374 E:379 ||| IN
painful  ||| S:379 E:387 ||| JJ
symptoms  ||| S:387 E:396 ||| NNS
since  ||| S:396 E:402 ||| IN
she  ||| S:402 E:406 ||| PRP
had  ||| S:406 E:410 ||| VBD
forgotten  ||| S:410 E:420 ||| VBN
to  ||| S:420 E:423 ||| TO
take  ||| S:423 E:428 ||| VB
her  ||| S:428 E:432 ||| PRP$
aspartame ||| S:432 E:441 ||| NN
.  ||| S:441 E:443 ||| .
All  ||| S:443 E:447 ||| DT
of  ||| S:447 E:450 ||| IN
the  ||| S:450 E:454 ||| DT
symptoms  ||| S:454 E:463 ||| JJ
reappeared  ||| S:463 E:474 ||| NN
in  ||| S:474 E:477 ||| IN
the  ||| S:477 E:481 ||| DT
days  ||| S:481 E:486 ||| NNS
following  ||| S:486 E:496 ||| VBG
her  ||| S:496 E:500 ||| PRP$
return  ||| S:500 E:507 ||| NN
when  ||| S:507 E:512 ||| WRB
she  ||| S:512 E:516 ||| PRP
reintroduced  ||| S:516 E:529 ||| VBP
aspartame  ||| S:529 E:539 ||| VBN
into  ||| S:539 E:544 ||| IN
her  ||| S:544 E:548 ||| PRP$
daily  ||| S:548 E:554 ||| JJ
diet ||| S:554 E:558 ||| NN
.  ||| S:558 E:560 ||| .
Thus ||| S:560 E:564 ||| RB
,  ||| S:564 E:566 ||| ,
aspartame  ||| S:566 E:576 ||| NN
was  ||| S:576 E:580 ||| VBD
definitively  ||| S:580 E:593 ||| RB
excluded  ||| S:593 E:602 ||| VBN
from  ||| S:602 E:607 ||| IN
her  ||| S:607 E:611 ||| PRP$
diet ||| S:611 E:615 ||| NN
,  ||| S:615 E:617 ||| ,
resulting  ||| S:617 E:627 ||| VBG
in  ||| S:627 E:630 ||| IN
a  ||| S:630 E:632 ||| DT
complete  ||| S:632 E:641 ||| JJ
regression  ||| S:641 E:652 ||| NN
of  ||| S:652 E:655 ||| IN
the  ||| S:655 E:659 ||| DT
fibromyalgia  ||| S:659 E:672 ||| JJ
symptoms ||| S:672 E:680 ||| NNS
.  ||| S:680 E:682 ||| .
A  ||| S:682 E:684 ||| DT
43-year-old  ||| S:684 E:696 ||| JJ
man  ||| S:696 E:700 ||| NN
consulted  ||| S:700 E:710 ||| VBN
for  ||| S:710 E:714 ||| IN
a  ||| S:714 E:716 ||| DT
3-year  ||| S:716 E:723 ||| JJ
history  ||| S:723 E:731 ||| NN
of  ||| S:731 E:734 ||| IN
bilateral  ||| S:734 E:744 ||| JJ
forearm ||| S:744 E:751 ||| NN
,  ||| S:751 E:753 ||| ,
wrist ||| S:753 E:758 ||| NN
,  ||| S:758 E:760 ||| ,
and  ||| S:760 E:764 ||| CC
hand  ||| S:764 E:769 ||| NN
and  ||| S:769 E:773 ||| CC
cervical  ||| S:773 E:782 ||| JJ
pain  ||| S:782 E:787 ||| NN
with  ||| S:787 E:792 ||| IN
various  ||| S:792 E:800 ||| JJ
unsuccessful  ||| S:800 E:813 ||| JJ
treatments ||| S:813 E:823 ||| NNS
.  ||| S:823 E:825 ||| .
A  ||| S:825 E:827 ||| DT
detailed  ||| S:827 E:836 ||| JJ
questioning  ||| S:836 E:848 ||| VBG
allowed  ||| S:848 E:856 ||| VBN
to  ||| S:856 E:859 ||| TO
find  ||| S:859 E:864 ||| VB
out  ||| S:864 E:868 ||| RP
that  ||| S:868 E:873 ||| IN
he  ||| S:873 E:876 ||| PRP
had  ||| S:876 E:880 ||| VBD
been  ||| S:880 E:885 ||| VBN
taking  ||| S:885 E:892 ||| VBG
aspartame  ||| S:892 E:902 ||| NN
for  ||| S:902 E:906 ||| IN
three  ||| S:906 E:912 ||| CD
years ||| S:912 E:917 ||| NNS
.  ||| S:917 E:919 ||| .
The  ||| S:919 E:923 ||| DT
removal  ||| S:923 E:931 ||| NN
of  ||| S:931 E:934 ||| IN
aspartame  ||| S:934 E:944 ||| NN
was  ||| S:944 E:948 ||| VBD
followed  ||| S:948 E:957 ||| VBN
by  ||| S:957 E:960 ||| IN
a  ||| S:960 E:962 ||| DT
complete  ||| S:962 E:971 ||| JJ
regression  ||| S:971 E:982 ||| NN
of  ||| S:982 E:985 ||| IN
pain ||| S:985 E:989 ||| NN
,  ||| S:989 E:991 ||| ,
without  ||| S:991 E:999 ||| IN
recurrence ||| S:999 E:1009 ||| NN
.  ||| S:1009 E:1011 ||| .
We  ||| S:1011 E:1014 ||| PRP
believe  ||| S:1014 E:1022 ||| VBP
that  ||| S:1022 E:1027 ||| IN
these  ||| S:1027 E:1033 ||| DT
patients ||| S:1033 E:1041 ||| NNS
'  ||| S:1041 E:1043 ||| POS
chronic  ||| S:1043 E:1051 ||| JJ
pain  ||| S:1051 E:1056 ||| NN
was  ||| S:1056 E:1060 ||| VBD
due  ||| S:1060 E:1064 ||| JJ
to  ||| S:1064 E:1067 ||| TO
the  ||| S:1067 E:1071 ||| DT
ingestion  ||| S:1071 E:1081 ||| NN
of  ||| S:1081 E:1084 ||| IN
aspartame ||| S:1084 E:1093 ||| NN
,  ||| S:1093 E:1095 ||| ,
a  ||| S:1095 E:1097 ||| DT
potent  ||| S:1097 E:1104 ||| JJ
flavouring  ||| S:1104 E:1115 ||| JJ
agent ||| S:1115 E:1120 ||| NN
,  ||| S:1120 E:1122 ||| ,
widely  ||| S:1122 E:1129 ||| RB
used  ||| S:1129 E:1134 ||| VBN
in  ||| S:1134 E:1137 ||| IN
food  ||| S:1137 E:1142 ||| NN
as  ||| S:1142 E:1145 ||| IN
a  ||| S:1145 E:1147 ||| DT
calorie-saver ||| S:1147 E:1160 ||| JJ
.  ||| S:1160 E:1162 ||| .
The  ||| S:1162 E:1166 ||| DT
benefit ||| S:1166 E:1173 ||| NN
/  ||| S:1173 E:1175 ||| CD
risk  ||| S:1175 E:1180 ||| NN
ratio  ||| S:1180 E:1186 ||| NN
of  ||| S:1186 E:1189 ||| IN
considering  ||| S:1189 E:1201 ||| VBG
the  ||| S:1201 E:1205 ||| DT
diagnosis  ||| S:1205 E:1215 ||| NN
of  ||| S:1215 E:1218 ||| IN
aspartame-induced  ||| S:1218 E:1236 ||| JJ
chronic  ||| S:1236 E:1244 ||| JJ
pain  ||| S:1244 E:1249 ||| NN
is  ||| S:1249 E:1252 ||| VBZ
obvious ||| S:1252 E:1259 ||| JJ
:  ||| S:1259 E:1261 ||| :
the  ||| S:1261 E:1265 ||| DT
potential  ||| S:1265 E:1275 ||| JJ
benefit  ||| S:1275 E:1283 ||| NN
is  ||| S:1283 E:1286 ||| VBZ
to  ||| S:1286 E:1289 ||| TO
cure  ||| S:1289 E:1294 ||| VB
a  ||| S:1294 E:1296 ||| DT
disabling  ||| S:1296 E:1306 ||| JJ
chronic  ||| S:1306 E:1314 ||| JJ
disease ||| S:1314 E:1321 ||| NN
,  ||| S:1321 E:1323 ||| ,
to  ||| S:1323 E:1326 ||| TO
spare  ||| S:1326 E:1332 ||| VB
numerous  ||| S:1332 E:1341 ||| JJ
laboratory  ||| S:1341 E:1352 ||| NN
and  ||| S:1352 E:1356 ||| CC
imaging  ||| S:1356 E:1364 ||| JJ
investigations ||| S:1364 E:1378 ||| NNS
,  ||| S:1378 E:1380 ||| ,
and  ||| S:1380 E:1384 ||| CC
to  ||| S:1384 E:1387 ||| TO
avoid  ||| S:1387 E:1393 ||| VB
potentially  ||| S:1393 E:1405 ||| RB
harmful  ||| S:1405 E:1413 ||| JJ
therapies ||| S:1413 E:1422 ||| NNS
;  ||| S:1422 E:1424 ||| :
the  ||| S:1424 E:1428 ||| DT
potential  ||| S:1428 E:1438 ||| JJ
risk  ||| S:1438 E:1443 ||| NN
is  ||| S:1443 E:1446 ||| VBZ
to  ||| S:1446 E:1449 ||| TO
temporarily  ||| S:1449 E:1461 ||| RB
change  ||| S:1461 E:1468 ||| VB
the  ||| S:1468 E:1472 ||| DT
patient ||| S:1472 E:1479 ||| NN
's  ||| S:1479 E:1482 ||| POS
diet ||| S:1482 E:1486 ||| NN
.  ||| S:1486 E:1488 ||| .
Thus ||| S:1488 E:1492 ||| RB
,  ||| S:1492 E:1494 ||| ,
practitioners  ||| S:1494 E:1508 ||| NNS
should  ||| S:1508 E:1515 ||| MD
ask  ||| S:1515 E:1519 ||| VB
patients  ||| S:1519 E:1528 ||| NNS
suffering  ||| S:1528 E:1538 ||| VBG
from  ||| S:1538 E:1543 ||| IN
fibromyalgia  ||| S:1543 E:1556 ||| NN
about  ||| S:1556 E:1562 ||| IN
their  ||| S:1562 E:1568 ||| PRP$
intake  ||| S:1568 E:1575 ||| NN
of  ||| S:1575 E:1578 ||| IN
aspartame ||| S:1578 E:1587 ||| NN
.  ||| S:1587 E:1589 ||| .
In  ||| S:1589 E:1592 ||| IN
some  ||| S:1592 E:1597 ||| DT
cases ||| S:1597 E:1602 ||| NNS
,  ||| S:1602 E:1604 ||| ,
this  ||| S:1604 E:1609 ||| DT
simple  ||| S:1609 E:1616 ||| JJ
question  ||| S:1616 E:1625 ||| NN
might  ||| S:1625 E:1631 ||| MD
lead  ||| S:1631 E:1636 ||| VB
to  ||| S:1636 E:1639 ||| TO
the  ||| S:1639 E:1643 ||| DT
resolution  ||| S:1643 E:1654 ||| NN
of  ||| S:1654 E:1657 ||| IN
a  ||| S:1657 E:1659 ||| DT
disabling  ||| S:1659 E:1669 ||| JJ
chronic  ||| S:1669 E:1677 ||| JJ
disease ||| S:1677 E:1684 ||| NN
.  ||| S:1684 E:1686 ||| .
